Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

[Ethnicity and health policy: Building equitable solutions in the face of ethnic inequalities].

Del Pino S, Coates AR, Milton Guzmán J, Gómez-Salgado J, Ruiz-Frutos C.

Rev Esp Salud Publica. 2018 Sep 26;92. pii: e201809059. Spanish.

PMID:
30245505
2.

Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin.

Wicha SG, Clewe O, Svensson RJ, Gillespie SH, Hu Y, Coates ARM, Simonsson USH.

Clin Pharmacol Ther. 2018 Dec;104(6):1208-1218. doi: 10.1002/cpt.1102. Epub 2018 Jun 19.

3.

Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.

Liu Y, Pertinez H, Davies GR, Gillespie SH, Coates AR, Hu Y.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00190-18. doi: 10.1128/AAC.00190-18. Print 2018 Jul.

4.

Comparing the action of HT61 and chlorhexidine on natural and model Staphylococcus aureus membranes.

Hubbard AT, Coates AR, Harvey RD.

J Antibiot (Tokyo). 2017 Oct;70(10):1020-1025. doi: 10.1038/ja.2017.90. Epub 2017 Aug 2.

PMID:
28765589
5.

Mechanism of Action of a Membrane-Active Quinoline-Based Antimicrobial on Natural and Model Bacterial Membranes.

Hubbard AT, Barker R, Rehal R, Vandera KA, Harvey RD, Coates AR.

Biochemistry. 2017 Feb 28;56(8):1163-1174. doi: 10.1021/acs.biochem.6b01135. Epub 2017 Feb 13.

PMID:
28156093
6.

Indigenous Child Health in Brazil: The Evaluation of Impacts as a Human Rights Issue.

Coates AR, Del Pino Marchito S, Vitoy B.

Health Hum Rights. 2016 Jun;18(1):221-234.

7.

A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.

Clewe O, Aulin L, Hu Y, Coates AR, Simonsson US.

J Antimicrob Chemother. 2016 Apr;71(4):964-74. doi: 10.1093/jac/dkv416. Epub 2015 Dec 24.

8.

Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces.

Zaura E, Brandt BW, Teixeira de Mattos MJ, Buijs MJ, Caspers MP, Rashid MU, Weintraub A, Nord CE, Savell A, Hu Y, Coates AR, Hubank M, Spratt DA, Wilson M, Keijser BJ, Crielaard W.

MBio. 2015 Nov 10;6(6):e01693-15. doi: 10.1128/mBio.01693-15.

9.

HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model--a potential novel therapeutic target.

Hu Y, Liu A, Menendez MC, Garcia MJ, Oravcova K, Gillespie SH, Davies GR, Mitchison DA, Coates AR.

Tuberculosis (Edinb). 2015 Jan;95(1):31-6. doi: 10.1016/j.tube.2014.11.002. Epub 2014 Nov 20.

PMID:
25481272
10.

Identification of the monocyte activating motif in Mycobacterium tuberculosis chaperonin 60.1.

Hu Y, Coates AR, Liu A, Lund PA, Henderson B.

Tuberculosis (Edinb). 2013 Jul;93(4):442-7. doi: 10.1016/j.tube.2013.04.001. Epub 2013 May 3.

PMID:
23643849
11.

Handwashing adherence by visitors is poor: is there a simple solution?

Willison-Parry TA, Haidar EA, Martini LG, Coates AR.

Am J Infect Control. 2013 Oct;41(10):928-9. doi: 10.1016/j.ajic.2013.01.023. Epub 2013 Apr 19.

PMID:
23608046
12.

Contradictory results with high-dosage rifamycin in mice and humans.

Coates AR, Hu Y, Jindani A, Mitchison DA.

Antimicrob Agents Chemother. 2013 Feb;57(2):1103. doi: 10.1128/AAC.01705-12. No abstract available.

13.

Antibiotics in phase II and III clinical trials.

Coates AR, Halls G.

Handb Exp Pharmacol. 2012;(211):167-83. doi: 10.1007/978-3-642-28951-4_11. Review.

PMID:
23090602
14.
15.

Mycobacterium tuberculosis chaperonin 60.1 inhibits leukocyte diapedesis in a murine model of allergic lung inflammation.

Riffo-Vasquez Y, Coates AR, Page CP, Spina D.

Am J Respir Cell Mol Biol. 2012 Aug;47(2):245-52. doi: 10.1165/rcmb.2011-0412OC. Epub 2012 Mar 23.

PMID:
22447969
16.

Mycobacterium tuberculosis acg gene is required for growth and virulence in vivo.

Hu Y, Coates AR.

PLoS One. 2011;6(6):e20958. doi: 10.1371/journal.pone.0020958. Epub 2011 Jun 8.

17.

HPLC/MS/MS methodology for sensitive quantitation of monic acid A, the metabolic product of the antibiotic mupirocin.

Haidar EA, Lee TD, Barton JD, Coates AR, Mantle PG.

Biomarkers. 2011 Aug;16(5):422-5. doi: 10.3109/1354750X.2011.582153. Epub 2011 May 20.

PMID:
21595607
18.

Novel classes of antibiotics or more of the same?

Coates AR, Halls G, Hu Y.

Br J Pharmacol. 2011 May;163(1):184-94. doi: 10.1111/j.1476-5381.2011.01250.x. Review.

19.

Comparison of the moonlighting actions of the two highly homologous chaperonin 60 proteins of Mycobacterium tuberculosis.

Cehovin A, Coates AR, Hu Y, Riffo-Vasquez Y, Tormay P, Botanch C, Altare F, Henderson B.

Infect Immun. 2010 Jul;78(7):3196-206. doi: 10.1128/IAI.01379-09. Epub 2010 Apr 26.

20.

Multiple moonlighting functions of mycobacterial molecular chaperones.

Henderson B, Lund PA, Coates AR.

Tuberculosis (Edinb). 2010 Mar;90(2):119-24. doi: 10.1016/j.tube.2010.01.004. Epub 2010 Mar 24. Review.

PMID:
20338810
21.

Caught with their PAMPs down? The extracellular signalling actions of molecular chaperones are not due to microbial contaminants.

Henderson B, Calderwood SK, Coates AR, Cohen I, van Eden W, Lehner T, Pockley AG.

Cell Stress Chaperones. 2010 Mar;15(2):123-41. doi: 10.1007/s12192-009-0137-6. Review.

22.

Acute and persistent Mycobacterium tuberculosis infections depend on the thiol peroxidase TpX.

Hu Y, Coates AR.

PLoS One. 2009;4(4):e5150. doi: 10.1371/journal.pone.0005150. Epub 2009 Apr 2.

23.

A biphasic response from bladder epithelial cells induced by catheter material and bacteria: an in vitro study of the pathophysiology of catheter related urinary tract infection.

Barford JM, Hu Y, Anson K, Coates AR.

J Urol. 2008 Oct;180(4):1522-6. doi: 10.1016/j.juro.2008.06.012. Epub 2008 Aug 16.

PMID:
18710771
24.

The two homologous chaperonin 60 proteins of Mycobacterium tuberculosis have distinct effects on monocyte differentiation into osteoclasts.

Winrow VR, Mesher J, Meghji S, Morris CJ, Maguire M, Fox S, Coates AR, Tormay P, Blake DR, Henderson B.

Cell Microbiol. 2008 Oct;10(10):2091-104. doi: 10.1111/j.1462-5822.2008.01193.x. Epub 2008 Jul 10.

PMID:
18616692
25.

Chaperonin 60 and macrophage activation.

Coates AR, Cehovin A, Hu Y.

Novartis Found Symp. 2008;291:160-9; discussion 169-72, 221-4.

PMID:
18575272
26.

A model of catheter-associated urinary tract infection initiated by bacterial contamination of the catheter tip.

Barford JM, Anson K, Hu Y, Coates AR.

BJU Int. 2008 Jul;102(1):67-74. doi: 10.1111/j.1464-410X.2008.07465.x. Epub 2008 Feb 18.

27.

Targeting non-multiplying organisms as a way to develop novel antimicrobials.

Coates AR, Hu Y.

Trends Pharmacol Sci. 2008 Mar;29(3):143-50. doi: 10.1016/j.tips.2007.12.001. Epub 2008 Feb 11. Review.

PMID:
18262665
28.

Plasma heat shock protein 60 and cardiovascular disease risk: the role of psychosocial, genetic, and biological factors.

Shamaei-Tousi A, Steptoe A, O'Donnell K, Palmen J, Stephens JW, Hurel SJ, Marmot M, Homer K, D'Aiuto F, Coates AR, Humphries SE, Henderson B.

Cell Stress Chaperones. 2007 Winter;12(4):384-92.

29.

A Mycobacterium tuberculosis mutant lacking the groEL homologue cpn60.1 is viable but fails to induce an inflammatory response in animal models of infection.

Hu Y, Henderson B, Lund PA, Tormay P, Ahmed MT, Gurcha SS, Besra GS, Coates AR.

Infect Immun. 2008 Apr;76(4):1535-46. doi: 10.1128/IAI.01078-07. Epub 2008 Jan 28.

30.
31.

Differential regulation of circulating levels of molecular chaperones in patients undergoing treatment for periodontal disease.

Shamaei-Tousi A, D'Aiuto F, Nibali L, Steptoe A, Coates AR, Parkar M, Donos N, Henderson B.

PLoS One. 2007 Nov 21;2(11):e1198.

32.

Reduced diversity in the early fecal microbiota of infants with atopic eczema.

Wang M, Karlsson C, Olsson C, Adlerberth I, Wold AE, Strachan DP, Martricardi PM, Aberg N, Perkin MR, Tripodi S, Coates AR, Hesselmar B, Saalman R, Molin G, Ahrné S.

J Allergy Clin Immunol. 2008 Jan;121(1):129-34. Epub 2007 Oct 29.

PMID:
18028995
33.

Novel approaches to developing new antibiotics for bacterial infections.

Coates AR, Hu Y.

Br J Pharmacol. 2007 Dec;152(8):1147-54. Epub 2007 Aug 20. Review.

34.

Gut microbiota and development of atopic eczema in 3 European birth cohorts.

Adlerberth I, Strachan DP, Matricardi PM, Ahrné S, Orfei L, Aberg N, Perkin MR, Tripodi S, Hesselmar B, Saalman R, Coates AR, Bonanno CL, Panetta V, Wold AE.

J Allergy Clin Immunol. 2007 Aug;120(2):343-50. Epub 2007 Jun 29.

PMID:
17604093
35.

Protective effect of human heat shock protein 60 suggested by its association with decreased seropositivity to pathogens.

Steptoe A, Shamaei-Tousi A, Gylfe A, Bailey L, Bergström S, Coates AR, Henderson B.

Clin Vaccine Immunol. 2007 Feb;14(2):204-7. Epub 2007 Jan 3.

36.

Highly homologous Mycobacterium tuberculosis chaperonin 60 proteins with differential CD14 dependencies stimulate cytokine production by human monocytes through cooperative activation of p38 and ERK1/2 mitogen-activated protein kinases.

Lewthwaite JC, Clarkin CE, Coates AR, Poole S, Lawrence RA, Wheeler-Jones CP, Pitsillides AA, Singh M, Henderson B.

Int Immunopharmacol. 2007 Feb;7(2):230-40. Epub 2006 Nov 20.

PMID:
17178391
37.

Stress wars: the direct role of host and bacterial molecular chaperones in bacterial infection.

Henderson B, Allan E, Coates AR.

Infect Immun. 2006 Jul;74(7):3693-706. Review. No abstract available.

38.

Association between plasma levels of heat shock protein 60 and cardiovascular disease in patients with diabetes mellitus.

Shamaei-Tousi A, Stephens JW, Bin R, Cooper JA, Steptoe A, Coates AR, Henderson B, Humphries SE.

Eur Heart J. 2006 Jul;27(13):1565-70. Epub 2006 Jun 8.

PMID:
16762985
39.
40.

Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.

Hu Y, Coates AR, Mitchison DA.

Int J Tuberc Lung Dis. 2006 Mar;10(3):317-22.

PMID:
16562713
41.
42.

Circulating human heat shock protein 60 in the blood of healthy teenagers: a novel determinant of endothelial dysfunction and early vascular injury?

Halcox JP, Deanfield J, Shamaei-Tousi A, Henderson B, Steptoe A, Coates AR, Singhal A, Lucas A.

Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):e141-2. No abstract available.

PMID:
16258145
43.

The unusual chaperonins of Mycobacterium tuberculosis.

Qamra R, Mande SC, Coates AR, Henderson B.

Tuberculosis (Edinb). 2005 Sep-Nov;85(5-6):385-94. Epub 2005 Oct 25. Review.

PMID:
16253564
44.

Comparative cell signalling activity of ultrapure recombinant chaperonin 60 proteins from prokaryotes and eukaryotes.

Maguire M, Poole S, Coates AR, Tormay P, Wheeler-Jones C, Henderson B.

Immunology. 2005 Jun;115(2):231-8.

45.

The intercellular signaling activity of the Mycobacterium tuberculosis chaperonin 60.1 protein resides in the equatorial domain.

Tormay P, Coates AR, Henderson B.

J Biol Chem. 2005 Apr 8;280(14):14272-7. Epub 2005 Jan 26.

46.
47.

Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs.

Mitchison DA, Coates AR.

Curr Pharm Des. 2004;10(26):3285-95. Review.

PMID:
15544516
48.

The Mycobacterium tuberculosis chaperonin 10 monomer exhibits structural plasticity.

Fossati G, Cremonesi P, Izzo G, Rizzi E, Sandrone G, Harding S, Errington N, Walters C, Henderson B, Roberts MM, Coates AR, Mascagni P.

Biopolymers. 2004 Oct 5;75(2):148-62.

PMID:
15356869
49.

The Mycobacterium tuberculosis sigJ gene controls sensitivity of the bacterium to hydrogen peroxide.

Hu Y, Kendall S, Stoker NG, Coates AR.

FEMS Microbiol Lett. 2004 Aug 15;237(2):415-23.

50.

Chaperonins are cell-signalling proteins: the unfolding biology of molecular chaperones.

Ranford JC, Coates AR, Henderson B.

Expert Rev Mol Med. 2000 Sep 15;2(8):1-17. doi: 10.1017/S1462399400002015.

PMID:
14585136

Supplemental Content

Loading ...
Support Center